Detalles de la búsqueda
1.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer
; 154(6): 1043-1056, 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37994647
2.
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
J Hepatol
; 80(3): 431-442, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37972660
3.
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology.
Oncology
; 102(2): 157-167, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37699372
4.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(12): 1399-1410, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38039993
5.
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
Br J Cancer
; 128(7): 1391-1399, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36759721
6.
Dynamic Profiling of the Immune Tumor Microenvironment in Locally Advanced Gastric Cancer Treated with Perioperative Chemotherapy.
Oncology
; 101(7): 435-445, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37307799
7.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology
; 101(5): 283-291, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36657420
8.
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action.
Gastric Cancer
; 26(6): 958-968, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37382783
9.
Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies.
Int J Clin Oncol
; 28(3): 363-369, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36689013
10.
Advances, Challenges, and Future Perspectives of Microwave Reflectometry for Plasma Position and Shape Control on Future Nuclear Fusion Devices.
Sensors (Basel)
; 23(8)2023 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37112274
11.
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 23(7): 876-887, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35636444
12.
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Br J Cancer
; 127(5): 957-967, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35665778
13.
Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib.
Future Oncol
; 18(27): 3021-3030, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35903991
14.
Upper transversal hepatectomy with double hepatic vein resection and reconstruction to treat colorectal cancer liver metastases at the hepatocaval confluence: a strategy to achieve R0 liver-sparing resection.
Langenbecks Arch Surg
; 407(4): 1741-1750, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35028737
15.
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
Br J Cancer
; 125(6): 839-845, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34253871
16.
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Br J Cancer
; 124(1): 183-190, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33024268
17.
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Oncologist
; 26(4): 302-309, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33336844
18.
Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis.
Liver Int
; 41(6): 1389-1397, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33547848
19.
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
Liver Int
; 41(12): 2997-3008, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34250737
20.
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib.
Hepatol Res
; 51(7): 796-802, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34005839